Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2005 1
2006 1
2008 1
2009 1
2011 1
2013 2
2014 2
2015 4
2016 2
2018 5
2019 2
2020 4
2021 1
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

29 results

Results by year

Filters applied: . Clear all
Page 1
Uterine Carcinosarcomas - Diagnosis and Management.
Denschlag D, Ulrich UA. Denschlag D, et al. Oncol Res Treat. 2018;41(11):675-679. doi: 10.1159/000494335. Epub 2018 Oct 13. Oncol Res Treat. 2018. PMID: 30317231 Review.
Uterine carcinosarcomas are rare tumors that account for less than 5% of all uterine malignancies. ...They are considered a high-risk variant of endometrial adenocarcinoma because carcinosarcomas share more similarities in epidemiology, risk factors, and clinical be …
Uterine carcinosarcomas are rare tumors that account for less than 5% of all uterine malignancies. ...They are considered a hi …
Review of Recommended Treatment of Uterine Carcinosarcoma.
Menczer J. Menczer J. Curr Treat Options Oncol. 2015 Nov;16(11):53. doi: 10.1007/s11864-015-0370-4. Curr Treat Options Oncol. 2015. PMID: 26374341 Review.
Surgery is the primary treatment for uterine carcinosarcoma (UCS). Lymphadenectomy should be performed for staging purposes in tumors apparently confined to the uterus. Most studies found that lymphadenectomy is of therapeutic value. The therapeutic va …
Surgery is the primary treatment for uterine carcinosarcoma (UCS). Lymphadenectomy should be performed for staging purposes in …
Beyond Serous: Treatment Options for Rare Endometrial Cancers.
Crane E. Crane E. Curr Treat Options Oncol. 2022 Nov;23(11):1590-1600. doi: 10.1007/s11864-022-01014-7. Epub 2022 Oct 7. Curr Treat Options Oncol. 2022. PMID: 36205807 Review.
Rare endometrial cancers are high-grade, aggressive malignancies which are often diagnosed at an advanced stage, and account for disproportionately more deaths than their more common low-grade counterparts. Standard of care includes a combination of surgery, radiation, and …
Rare endometrial cancers are high-grade, aggressive malignancies which are often diagnosed at an advanced stage, and account for disproporti …
Management and Prognosis of Patients with Recurrent or Persistent/Progressive Uterine Carcinosarcoma.
Tung HJ, Chiang CY, Chang WY, Wu RC, Huang HJ, Yang LY, Lin CY, Wang CC, Chao A, Lai CH. Tung HJ, et al. Curr Oncol. 2022 Oct 13;29(10):7607-7623. doi: 10.3390/curroncol29100601. Curr Oncol. 2022. PMID: 36290878 Free PMC article.
Uterine carcinosarcoma (UCS) is a highly aggressive gynecologic malignancy. ...Salvage therapy using radiotherapy or chemotherapy or CRT significantly improved SAR. ...
Uterine carcinosarcoma (UCS) is a highly aggressive gynecologic malignancy. ...Salvage therapy using radiotherapy or ch …
Monitoring Treatment Response, Early Recurrence, and Survival in Uterine Serous Carcinoma and Carcinosarcoma Patients Using Personalized Circulating Tumor DNA Biomarkers.
Bellone S, McNamara B, Mutlu L, Demirkiran C, Hartwich TMP, Harold J, Yang-Hartwich Y, Siegel ER, Santin AD. Bellone S, et al. Int J Mol Sci. 2023 May 17;24(10):8873. doi: 10.3390/ijms24108873. Int J Mol Sci. 2023. PMID: 37240216 Free PMC article.
Uterine serous carcinoma (USC) and carcinosarcomas (CSs) are rare, highly aggressive variants of endometrial cancer. ...
Uterine serous carcinoma (USC) and carcinosarcomas (CSs) are rare, highly aggressive variants of endometrial cancer. ...
Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma.
Ebata T, Yonemori K, Nishikawa T, Sudo K, Shimomura A, Noguchi E, Fujiwara Y, Kato T, Hasegawa K, Fujiwara K, Tamura K. Ebata T, et al. Oncology. 2020;98(10):699-705. doi: 10.1159/000507333. Epub 2020 Jun 11. Oncology. 2020. PMID: 32526764
INTRODUCTION: Carcinosarcoma is a rare cancer, and its prognosis is poor. There are few reports on the prognostic factors of patients with carcinosarcoma who receive second-line chemotherapy. OBJECTIVE: To investigate the outcome and prognostic factors of patients w …
INTRODUCTION: Carcinosarcoma is a rare cancer, and its prognosis is poor. There are few reports on the prognostic factors of patients …
Rare uterine cancer: carcinosarcomas. Review from histology to treatment.
Artioli G, Wabersich J, Ludwig K, Gardiman MP, Borgato L, Garbin F. Artioli G, et al. Crit Rev Oncol Hematol. 2015 Apr;94(1):98-104. doi: 10.1016/j.critrevonc.2014.10.013. Epub 2014 Nov 7. Crit Rev Oncol Hematol. 2015. PMID: 25468677 Review.
Uterine carcinosarcoma (UCS) is an aggressive malignancy. With an incidence of 2/100,000 females and a 5 years Survival at stage IV of 0%, it is an uncommon type of cancer with a very poor prognosis. ...
Uterine carcinosarcoma (UCS) is an aggressive malignancy. With an incidence of 2/100,000 females and a 5 years Survival at sta …
Adjuvant Treatment Modalities, Prognostic Factors, and Outcome of the Uterine Carcinosarcoma.
Kahramanoglu I, Demirkiran F, Turan H, Bese T, Cebi S, Ilvan S, Arvas M. Kahramanoglu I, et al. J Obstet Gynaecol Can. 2021 Jan;43(1):34-42. doi: 10.1016/j.jogc.2020.06.021. Epub 2020 Jul 18. J Obstet Gynaecol Can. 2021. PMID: 33041218
OBJECTIVE: To determine the impact of adjuvant therapy and other factors associated with the recurrence and survival of patients with uterine carcinosarcoma (UCS). ...
OBJECTIVE: To determine the impact of adjuvant therapy and other factors associated with the recurrence and survival of patients with …
Adjuvant radiotherapy for uterine carcinosarcoma: A retrospective assessment of treatment outcomes.
Yilmaz U, Alanyali S, Aras AB, Ozsaran Z. Yilmaz U, et al. J Cancer Res Ther. 2019 Oct-Dec;15(6):1377-1382. doi: 10.4103/jcrt.JCRT_531_18. J Cancer Res Ther. 2019. PMID: 31898676 Free article.
OBJECTIVES: The objective of the study is to understand the impact of adjuvant radiotherapy (RT) and prognostic factors for patients diagnosed with uterine carcinosarcoma. MATERIALS AND METHODS: The records of 31 patients receiving adjuvant RT between the dates of S …
OBJECTIVES: The objective of the study is to understand the impact of adjuvant radiotherapy (RT) and prognostic factors for patients diagnos …
APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S, Li Y, Xu J, Shen L. Zhao S, et al. Neurol Res. 2024 Mar;46(3):227-242. doi: 10.1080/01616412.2023.2287340. Epub 2024 Jan 22. Neurol Res. 2024. PMID: 38007705
Developing drugs to block A3C could enhance the efficiency of immunotherapy and improve disease survival.Abbreviation: A3C: Apolipoprotein B mRNA editing catalytic polypeptide-like (APOBEC) type 3C; LGGs: lower-grade gliomas; CGGA: Chinese Glioma Genome Atlas; WGCNA: Weighted gen …
Developing drugs to block A3C could enhance the efficiency of immunotherapy and improve disease survival.Abbreviation: A3C: Apolipoprotein B …
29 results